PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE
Details
- Status
- Prescription
- First Approved
- 2013-01-04
- Routes
- ORAL
- Dosage Forms
- TABLET
PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE Approval History
What PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE Treats
3 indicationsPIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE is approved for 3 conditions since its original approval in 2013. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Type 2 Diabetes
- Type 1 Diabetes
- Diabetic Ketoacidosis
Drugs Similar to PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE FDA Label Details
ProIndications & Usage
Glimepiride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see Clinical Studies ]. Limitations of Use Glimepiride tablets should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be effective in these settings. Glimepiride tablets are a sulfonylurea indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus . Limitations of Use: Not for treating type 1 diabetes mellitus or diabetic ketoacidosis .
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.